Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1995681 | 0.81 | KEAP1 (0.32) | DGAT1 | |
| SCHEMBL10883543 | 0.80 | CTSK (0.39) | CTSKMEN1KMT2ATDP1DGAT1 | |
| SCHEMBL3926929 | 0.80 | TDP1 (0.36) | CTSKMEN1KMT2AMAPK1APLNR | |
| SCHEMBL24517966 | 0.80 | TDP1 (0.36) | CTSKMEN1KMT2AMAPK1APLNR | |
| SCHEMBL5168488 | 0.79 | CTSK (0.36) | CTSKMEN1KMT2AMAPK1TDP1 | |
| SCHEMBL29012774 | 0.78 | CTSK (0.41) | CTSKMEN1KMT2AMAPK1APLNR | |
| SCHEMBL12691730 | 0.78 | CA1 (0.42) | CTSKMEN1KMT2AAPLNRTDP1 | |
| SCHEMBL3374338 | 0.78 | CA1 (0.40) | CTSKMEN1KMT2ATDP1DGAT1 | |
| SCHEMBL15465871 | 0.77 | MIF (0.36) | CTSKMEN1KMT2AMAPK1TDP1 | |
| SCHEMBL20057244 | 0.77 | MIF (0.36) | CTSKMEN1KMT2AMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-23 | — | — | US | disclosed |
| US-12599616-B2 | Subtituted sulfonylurea and sulfoximineurea derivatives | ZYDUS LIFESCIENCES LIMITED (IN) | 2026-04-14 | — | — | US | disclosed |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
| EP-3912979-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2026-02-19 | — | — | US | disclosed |
| EP-4688738-A1 | HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688159-A1 | PARG INHIBITORY COMPOUNDS | FoRx Therapeutics AG (CH) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025264700-A1 | GIP RECEPTOR AGONIST COMPOUNDS | ELI LILLY AND COMPANY (US) | 2025-12-26 | — | — | WO | disclosed |
| US-4843072-A | Antihypertensive pyridazinone aminoisopropanol derivatives | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1989-06-27 | — | — | US | disclosed |
| EP-0259835-A2 | Pyridazinone derivatives | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1988-03-16 | — | — | EP | disclosed |
| US-4701552-A | ARTIFICIAL SWEETENERS | GENERAL FOODS CORPORATION (US) | 1987-10-20 | — | — | US | disclosed |
| US-4678675-A | Sweetening with L-aminodicarboxylic acid alkenes | GENERAL FOODS CORPORATION (US) | 1987-07-07 | — | — | US | disclosed |
| US-4652676-A | L-aminodicarboxylic acid alkenes | GENERAL FOODS CORPORATION (US) | 1987-03-24 | — | — | US | disclosed |
| EP-0203540-A1 | L-Aminodicarboxylic acid amides of substituted amines and a composition containing the same | GENERAL FOODS CORPORATION (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0201844-A1 | L-Aminodicarboxylic acid alkenes and an edible composition containing same | GENERAL FOODS CORPORATION (US) | 1986-11-20 | — | — | EP | disclosed |
| EP-0201077-A1 | L-Aminodicarboxylic acid alkanes and an edible composition containing same | GENERAL FOODS CORPORATION (US) | 1986-11-12 | — | — | EP | disclosed |
| US-4622232-A | L-aminodicarboxylic acid alkanes | GENERAL FOODS CORPORATION (US) | 1986-11-11 | — | — | US | disclosed |
| US-4603012-A | L-aminodicarboxylic acid alkanes | GENERAL FOODS CORPORATION (US) | 1986-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | CTSK 1682/4885MEN1 800/4885KMT2A 2072/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | CTSK 2087/4885MEN1 3270/4885KMT2A 1684/4885 |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | CTSK 3711/4885MEN1 3404/4885KMT2A 3887/4885 |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SCN10A, KCNK10, KCNJ2 | CTSK 969/4885MEN1 2323/4885KMT2A 2195/4885 |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GCGR | CTSK 3676/4885MEN1 3224/4885KMT2A 4611/4885 |
| US-12599616-B2 | Subtituted sulfonylurea and sulfoximineurea derivatives | NOD1, NLRP3, NOD2 | CTSK 3678/4885MEN1 3629/4885KMT2A 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.